These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 34587977)

  • 21. SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1.
    Wang Z; Petricca J; Liu M; Zhang S; Chen S; Li M; Besschetnova A; Patalano S; Venkataramani K; Siegfried KR; Macoska JA; Han D; Gao S; Vedadi M; Arrowsmith CH; He HH; Cai C
    Proc Natl Acad Sci U S A; 2023 Aug; 120(33):e2220472120. PubMed ID: 37549269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methyltransferase inhibitor adenosine dialdehyde suppresses androgen receptor expression and prostate cancer growth.
    Shiota M; Takeuchi A; Yokomizo A; Kashiwagi E; Tatsugami K; Naito S
    J Urol; 2012 Jul; 188(1):300-6. PubMed ID: 22608750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Production of a Urinary Selenium Metabolite, Trimethylselenonium, by Thiopurine
    Fukumoto Y; Yamada H; Matsuhashi K; Okada W; Tanaka YK; Suzuki N; Ogra Y
    Chem Res Toxicol; 2020 Sep; 33(9):2467-2474. PubMed ID: 32786394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential molecular mechanisms of substrate recognition by selenium methyltransferases, INMT and TPMT, in selenium detoxification and excretion.
    Fukumoto Y; Kyono R; Shibukawa Y; Tanaka YK; Suzuki N; Ogra Y
    J Biol Chem; 2024 Feb; 300(2):105599. PubMed ID: 38159853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GR silencing impedes the progression of castration-resistant prostate cancer through the JAG1/NOTCH2 pathway via up-regulation of microRNA-143-3p.
    Zhang L; Jiang H; Zhang Y; Wang C; Xia X; Sun Y
    Cancer Biomark; 2020; 28(4):483-497. PubMed ID: 32568179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cdc20/p55 mediates the resistance to docetaxel in castration-resistant prostate cancer in a Bim-dependent manner.
    Wu F; Lin Y; Cui P; Li H; Zhang L; Sun Z; Huang S; Li S; Huang S; Zhao Q; Liu Q
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):999-1006. PubMed ID: 29605876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
    Abudurexiti M; Zhu W; Wang Y; Wang J; Xu W; Huang Y; Zhu Y; Shi G; Zhang H; Zhu Y; Shen Y; Dai B; Wan F; Lin G; Ye D
    Prostate; 2020 Sep; 80(12):950-961. PubMed ID: 32648618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer.
    Chen X; Liu J; Cheng L; Li C; Zhang Z; Bai Y; Wang R; Han T; Huang C; Kong Y; Feng F; Liu X
    Prostate; 2020 Feb; 80(3):256-266. PubMed ID: 31856338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
    Linder A; Larsson K; Welén K; Damber JE
    Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
    Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
    Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
    Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
    Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9.
    Cock-Rada AM; Medjkane S; Janski N; Yousfi N; Perichon M; Chaussepied M; Chluba J; Langsley G; Weitzman JB
    Cancer Res; 2012 Feb; 72(3):810-20. PubMed ID: 22194464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LPCAT1 enhances castration resistant prostate cancer progression via increased mRNA synthesis and PAF production.
    Han C; Yu G; Mao Y; Song S; Li L; Zhou L; Wang Z; Liu Y; Li M; Xu B
    PLoS One; 2020; 15(11):e0240801. PubMed ID: 33137125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NPRL2 promotes docetaxel chemoresistance in castration resistant prostate cancer cells by regulating autophagy through the mTOR pathway.
    Luo S; Shao L; Chen Z; Hu D; Jiang L; Tang W
    Exp Cell Res; 2020 May; 390(2):111981. PubMed ID: 32234375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MicroRNA-144-3p inhibits cell proliferation and promotes apoptosis in castration-resistant prostate cancer by targeting CEP55.
    You B; Zhang KC
    Eur Rev Med Pharmacol Sci; 2018 Nov; 22(22):7660-7670. PubMed ID: 30536308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer.
    Gu P; Chen X; Xie R; Xie W; Huang L; Dong W; Han J; Liu X; Shen J; Huang J; Lin T
    Mol Cancer; 2019 Jun; 18(1):109. PubMed ID: 31221168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SMYD3: a regulator of epigenetic and signaling pathways in cancer.
    Bernard BJ; Nigam N; Burkitt K; Saloura V
    Clin Epigenetics; 2021 Feb; 13(1):45. PubMed ID: 33637115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting GPR30 with G-1: a new therapeutic target for castration-resistant prostate cancer.
    Lam HM; Ouyang B; Chen J; Ying J; Wang J; Wu CL; Jia L; Medvedovic M; Vessella RL; Ho SM
    Endocr Relat Cancer; 2014; 21(6):903-14. PubMed ID: 25287069
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Indolethylamine-N-Methyltransferase Inhibits Proliferation and Promotes Apoptosis of Human Prostate Cancer Cells: A Mechanistic Exploration.
    Jianfeng W; Yutao W; Jianbin B
    Front Cell Dev Biol; 2022; 10():805402. PubMed ID: 35252179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multifocal Signal Modulation Therapy by Celecoxib: A Strategy for Managing Castration-Resistant Prostate Cancer.
    Benelli R; Barboro P; Costa D; Astigiano S; Barbieri O; Capaia M; Poggi A; Ferrari N
    Int J Mol Sci; 2019 Dec; 20(23):. PubMed ID: 31816863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.